The Investor’s Insider:
Protecting Against Securities Fraud

Posts Tagged ‘Misrepresentation’

United States Supreme Court Applies a “Reasonable Standard” to Corporations’ “Beliefs”

Posted on: March 24th, 2015 by Nadine Gartner

The United States Supreme Court issued today its opinion in Omnicare, Inc. v. Laborers Dist. Council, a case previously discussed here. Read more…

Stoll Berne Seeks Class Certification in “London Whale” Suit

Posted on: February 19th, 2015 by Keith Dubanevich

Stoll Berne, along with co-counsel Bernstein Litowitz Berger & Grossmann LLP, Grant & Eisenhofer PA, and Kessler Topaz Meltzer & Check LLP, has filed for class certification in its case against JPMorgan Chase & Co. Read more…

Pfizer to Pay $400M to Settle Shareholder Suit

Posted on: January 28th, 2015 by Nadine Gartner

Pharmaceutical company Pfizer Inc. has reached an agreement in principle to pay $400 million to settle a class-action securities lawsuit. Read more…

U.S. Supreme Court Upholds the Fraud-on-the-Market Doctrine

Posted on: June 23rd, 2014 by Keith Dubanevich

On June 23, 2014, the U.S. Supreme court issued its opinion in Halliburton Co. v. Erica P. John Fund, Inc. and upheld the fraud-on-the-market doctrine.  The doctrine sets forth that the market, including Wall Street analysts and other professional investors, reviews the material public information about the company and sets the price for a security based on that information. Read more…

Stoll Berne Investigates Galena Biopharma

Posted on: February 20th, 2014 by Nadine Gartner

Our firm is investigating potential claims concerning whether Galena Biopharma, Inc. (“Galena”) (NASDAQ: GALE), its board of directors and/or officers violated state or federal securities laws, or breached fiduciary duties owed to shareholders. Read more…

Oregon Supreme Court Rules That Proof of Reliance in Oregon Securities Law Action Can Be Established Via the Fraud-on-the-Market Doctrine

Posted on: December 13th, 2012 by Keith Ketterling

On December 13, 2012, the Oregon Supreme Court ruled unanimously that a plaintiff who brings a claim for damages based on misrepresentations under ORS 59.137(1) must establish that the plaintiff relied on the misrepresentations, but that proof of reliance can be established through the rebuttable presumption available under the fraud-on-the-market doctrine.  Read more…

Judge Grants Class Certification Over False Claims by Radient Pharmaceuticals

Posted on: December 4th, 2012 by Nadine Gartner

A federal judge in the Central District of California has certified a class of investors in a pending securities fraud lawsuit against Radient Pharmaceuticals. Read more…

Pfizer Settles Class Action Lawsuit by Former Wyeth Shareholders

Posted on: November 15th, 2012 by Keith Dubanevich

Pfizer Inc. (“Pfizer”), the world’s largest pharmaceutical company, has agreed to pay $67.5 million to settle a class action lawsuit by shareholders of the former Wyeth Inc. (“Wyeth”), a pharmaceutical company bought by Pfizer in 2009.  Read more…

Supreme Court Hears Case About Material Misstatements

Posted on: November 12th, 2012 by Nadine Gartner

In a previous post, we discussed that the Supreme Court had granted certiorari in Amgen Inc. v. Connecticut Retirement Plans.  The Court heard that case on Monday, November 5, 2012. Read more…

Public Corporations Use Foreign Tax Reserves to Manipulate Earnings

Posted on: October 30th, 2012 by Keith Dubanevich

A recent study demonstrates that a little-known accounting rule not only allows companies to set aside billions of dollars in overseas profits free of United States’ tax, but also helps public corporations manipulate their earnings.  Read more…

Pfizer to Pay $164 Million to Settle Celebrex Class Action

Posted on: October 16th, 2012 by Nadine Gartner

Pfizer Inc. has agreed to pay $164 million to settle a shareholder class action lawsuit involving Celebrex, an arthritis drug. Read more…

Legal Disclaimer

The information contained in this blog does not constitute legal advice, and does not create an attorney-client relationship. We make no claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained in or linked to this blog.

About this blog

The purpose of this blog is to provide information to the general public and to practitioners about developments that may impact Oregon investors.

About the author

  • Nadine Gartner

  • Nadine Gartner
  • Nadine Gartner’s practice focuses on complex business litigation and class actions. Prior to becoming a lawyer, Nadine worked as an investment banking analyst.
Follow stollberne on Twitter

Subscribe to this blog